Source: GlobeNewswire Inc.
Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, announced today that it priced an underwritten public offering of 3,300,000 of its ordinary shares at a price to the public of $37.00 per ordinary share, before the underwriting discount. All of the ordinary shares in the offering were sold by Prothena. In addition, Prothena has granted the underwriters a 30-day option to purchase up to an additional 495,000 of its ordinary shares.
Net proceeds to Prothena from the ordinary shares to be sold by Prothena in the offering are expected to be $114.2 million, after deducting the underwriting discount and estimated offering expenses, but excluding any exercise of the underwriters' option to purchase additional ordinary shares. The offering is expected to close on April 13, 2015, subject to customary closing conditions.
Credit Suisse, RBC Capital Markets and UBS Investment Bank are acting as joint book-running managers, and Oppenheimer & Co., Wedbush PacGrow, Ladenburg Thalmann and LifeSci Capital are acting as co-managers for the offering.
Recent PRTA News
- Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma • Business Wire • 04/15/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 02:03:16 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 02:01:40 AM
- Prothena to Participate in Upcoming Healthcare Conferences • Business Wire • 03/05/2024 09:05:00 PM
- Prothena Appoints David Ford to Newly Created Chief People Officer Position • Business Wire • 03/04/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 02:11:54 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 02:09:37 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 02:08:29 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 02:06:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 02:03:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 02:02:39 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 02:01:05 AM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 02/22/2024 10:29:39 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/22/2024 09:56:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 09:06:56 PM
- Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate • Business Wire • 02/21/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 09:09:11 PM
- Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights • Business Wire • 02/15/2024 09:05:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 05:16:26 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 12:49:22 AM
- Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024 • Business Wire • 02/08/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 12:01:06 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/24/2024 09:06:01 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM